ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV). 22 patients (22 eyes) with myopic CNV were included in the study. Mean age was 54.0 ± 14.4 years, axial length -28.25± 1.9 mm,follow-up-from 12 to 59 month...
Guardado en:
Autores principales: | S. A. Korotkikh, E. V. Bobykin, G. V. Zhiborkin, A. Y. Anashkin, A. V. Berezin |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/113add6fa8974e6a8fda12e9e7207145 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017) -
Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017) -
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
por: Korol AR, et al.
Publicado: (2016) -
Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
por: A. V. Grigorieva, et al.
Publicado: (2021) -
Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
por: Bhatia D, et al.
Publicado: (2021)